Spanish HealthTech startup Pragmatech has successfully secured $764,000 in a new funding round to advance its innovative medical software. The investment is earmarked for the commercial rollout of iAST®, its flagship AI-powered tool for antibiotic prescription support. This strategic move follows the product's recent achievement of the crucial CE marking, signaling its readiness for the European market.
Strategic Investment to Fuel Commercial Growth
The financing was spearheaded by venture capital firm First Drop, which contributed $353,000 to the round. Participation also came from Urriellu Ventures with a $205,000 investment, alongside a $211,000 loan from the national innovation agency ENISA. The total was further supplemented by the conversion of $191,150 in notes from a previous round.
With this capital, Pragmatech will focus on strengthening its commercial strategy and accelerating the adoption of iAST® in hospitals and clinics. The funding provides the necessary resources to scale operations and bring the clinically validated tool to healthcare professionals across Europe. The successful transaction was advised by the law firm AV Law, which guided the company through the process.
Pioneering AI in Antibiotic Prescription
Founded in 2021 and based in Oviedo, Pragmatech specializes in developing artificial intelligence solutions for complex healthcare challenges. Its premier product, iAST®, is distinguished as the first CE-marked AI software designed to guide clinical decisions in antibiotic use. The platform addresses critical issues in pharmacology, microbiology, and infectious diseases.
The iAST® system has been clinically proven to significantly reduce prescription errors, a major concern in modern medicine. By analyzing patient data, it recommends treatments with a lower potential for fostering antibiotic resistance, a growing global health threat. This capability enhances patient safety and supports more sustainable healthcare practices.
Leadership Vision and Market Position
Javier Fernández, co-CEO of Pragmatech, stated that the investment strengthens the company's capacity to deliver iAST® to medical professionals who need it most. He emphasized that the backing from investors like First Drop and Urriellu Ventures validates their technology's potential. This support reinforces confidence in the positive impact the software is having on clinical practice.
Co-CEO and CTO Pablo Valledor added that the funding extends beyond commercial deployment, enabling continuous product refinement. He noted the resources are crucial for ensuring that artificial intelligence safely and effectively supports clinical decision-making. This commitment to ongoing development underscores the company's focus on quality and reliability in its technology.
Operating on a B2B model, Pragmatech aims to become a leader in the digital transformation of infectious disease management. The company's overarching goal is to improve patient outcomes while simultaneously enhancing the long-term sustainability of healthcare systems. This new funding round is a significant step toward achieving that ambitious vision.
This $764,000 investment marks a pivotal moment for Pragmatech, empowering the company to transition from development to widespread commercialization. By deploying its CE-marked iAST® software, the startup is poised to make a substantial contribution to optimizing antibiotic use and improving patient care. The successful funding round solidifies its position as a key innovator in the European HealthTech landscape.